CRSP - CRISPR Therapeutics AG
| Previous Close | 33.44 |
| Open | 33.15 |
| Bid | 32.92 x 1400 |
| Ask | 32.96 x 800 |
| Day's Range | 32.76 - 33.99 |
| 52 Week Range | 18.66 - 73.90 |
| Volume | 388,164 |
| Avg. Volume | 991,769 |
| Market Cap | 1.711B |
| Beta (3Y Monthly) | 3.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.60 |
| Earnings Date | Mar 6, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 66.69 |
- Motley Fool•yesterday
3 High-Growth Stocks That Are Just Getting Started
Finding high-growth stocks in their early innings can reward long-term investors. Here are three to consider.
- Motley Fool•yesterday
Top 10 Healthcare Stories of 2018
New drugs, trial flops, M&A, and a little bit of everything else that happened in healthcare in 2018.
- InvestorPlace•4 days ago
Why CRSP Stock Has Added Layers of Risk
Biotech stocks like CRISPR Therapeutics (NASDAQ:CRSP) are inherently risky, and inherently volatile. CRISPR stock itself, only public for a little over two years, is a good example. CRSP stock went public at $14 — and cleared $70 this year.
- Motley Fool•4 days ago
Here's Why Crispr Therapeutics Rose 17% in November
The gene-editing pioneer reported third-quarter 2018 earnings and solid progress in the clinic.
- Motley Fool•4 days ago
Here's Why Editas Medicine Jumped 23% in November
The gene-editing pioneer reported third-quarter 2018 earnings and reported FDA acceptance of its first investigational new drug (IND) application.
- Yahoo Finance•13 days ago
Genetic editing is this week's champ — Fed's Powell is the chump
The gene editor that pulled HIV from an unborn baby is this week's champ. Fed Chair Jerome Powell, backing down to critics, is the chump.
- Zacks•14 days ago
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $38.33, marking a -1.01% move from the previous day.
- Investor's Business Daily•14 days ago
This Biotech Stock Could Launch Its First CRISPR Drug In 2022
Crispr Therapeutics will launch a gene-editing therapy in the U.S. in 2022, an analyst predicted Friday as he initiated coverage with a buy rating.
Motley Fool•14 days agoWhy Crispr Therapeutics Stock Is Up By 65% So Far in 2018
The gene-editing specialist has been a rare bright spot within the hard hit biotech space this year. Here's why.
- MarketWatch•18 days ago
With genetically edited babies, a scientist transgresses a moral boundary
A Chinese scientist from a university in Shenzhen claims he has succeeded in creating the world’s first genetically edited babies. We have no idea what effects the alteration of genes in sperm or ova or a fetus will have on future generations. CRISPRs evolved over millions of years to trim pieces of genetic information from one genome and insert it into another.
- American City Business Journals•18 days ago
Mass. biotech leaders voice alarm over report of first gene-edited babies
The researcher's claims, which have not yet been published in a scientific paper, prompted a swift outcry among Boston-area life sciences officials Monday, given that such genetic changes can be passed on to future generations.
- GlobeNewswire•23 days ago
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 21, 2018 -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
- Motley Fool•26 days ago
Better Buy: CRISPR Therapeutics AG vs. Sangamo Therapeutics Inc.
This battle goes beyond the merits of CRISPR and zinc-finger nuclease gene-editing approaches.
Market Realist•28 days agoEditas Stock: Analysts’ Recommendations
In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.” The mean rating for Editas Medicine stock is 2.4 with a target price of $47.29, which implies an upside potential of 75.8% over Editas Medicine’s closing price of $26.9 on November 14.
- GlobeNewswire•last month
New Research Coverage Highlights CAS Medical, Saia, Core Laboratories N.V, Perceptron, CRISPR Therapeutics AG, and IEC Electronics — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•last month
CRISPR Therapeutics AG (CRSP) Stock Moves -0.55%: What You Should Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $36.17, moving -0.55% from the previous trading session.
Market Realist•last monthCRISPR Therapeutics: Recent Developments and Earnings Overview
CRISPR Therapeutics (CRSP) reported a net income of -$50.7 million in the third quarter—compared to a net income of -$24.7 million in the third quarter of 2017. CRISPR Therapeutics’ net income over the first nine months of 2018 was -$117.4 million—compared to -$68.5 million in the same period in 2017.
InvestorPlace•last month3 DNA Stocks That Are on the Uptrend
The future of genetic medicine — and DNA stocks — is extremely bullish over the long term. But as is normal of any emerging technology, there will be plenty of bumps along the road. The good news is that those bumps will provide many opportunities to buy DNA stocks along the way.
Market Realist•last monthA Financial Overview of CRISPR Therapeutics in November
CRISPR Therapeutics (CRSP) reported revenues of $563,000 in the third quarter—compared to $2.4 million in the third quarter of 2017. CRISPR Therapeutics reported net revenues of $3.0 million over the first nine months of 2018—compared to $8.7 million during the same period in 2017. CRISPR Therapeutics’ net revenues are mainly from collaborations undertaken by the company.
Market Realist•last monthCRISPR Therapeutics: Analysts’ View in November
On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8. On November 7, after the company reported its third-quarter financial results, the stock price grew ~10.81% to $38.85 from the close of $35.06 on November 6.
- GlobeNewswire•last month
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
CRISPR Therapeutics (CRSP) and MaxCyte today announced the expansion of their existing relationship by entering into a non-exclusive commercial license agreement that will allow CRISPR Therapeutics to deploy MaxCyte’s Flow Electroporation® Technology to develop CRISPR/Cas9-based therapies in immuno-oncology. “As we advance our allogeneic CAR-T programs into the clinic, we are preparing for the future by securing our access to the leading ex vivo delivery platform for both clinical and commercial use, just as we previously did for our hemoglobinopathy developmental candidates,” said Samarth Kulkarni, CEO of CRISPR Therapeutics.
- American City Business Journals•last month
Cambridge's Editas asks FDA to start gene editing trial
Editas Medicine could be the next to test the widely watched gene editing technology CRISPR/Cas9 after filing a clinical trial application late last month, the company revealed Wednesday.
- GlobeNewswire•last month
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2018 Financial Results
-Initiated Phase 1/2 Clinical Trial of CTX001 in β-thalassemia- -Targeting Initiation of Clinical Trial for CTX110, Targeting CD19+ Malignancies, in 1H 2019--$487.3 Million in.
- Motley Fool•last month
Here's Why CRISPR Stocks Fell as Much as 40.7% in October
It was a busy month for gene editing stocks, which suffered from both CRISPR-specific news and the broader stock market's fall.
- Zacks•last month
ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance
ImmunoGen (IMGN) reports narrower-than-expected loss in Q3. However, it misses estimates for revenues. Shares down.
